ABBV vs COP: Which Is the Better Buy?
Side-by-side comparison of AbbVie Inc. and ConocoPhillips — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-07-08.
AbbVie Inc. · Healthcare
$261.07
+1.2% upside to fair value
Grade C
High Quality
VS
ConocoPhillips · Energy
$108.44
-21.6% upside to fair value
Grade D
QuantHub Verdict
ABBV has more upside to fair value
(+1.2%).
COP trades at a lower forward P/E
(18.4x).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
ABBV |
COP |
| Current Price |
$261.07 |
$108.44 |
| Fair Value Estimate |
$264.30 |
$85.04 |
| Upside to Fair Value |
+1.2%
|
-21.6%
|
| Market Cap |
$461.3B |
$132.1B |
| Forward P/E |
128.0x
|
18.4x
|
| EV / EBITDA |
31.0x
|
6.1x
|
| Price / Sales |
7.3x
|
2.3x
|
| Price / FCF |
22.1x
|
8.6x
|
| Revenue Growth YoY |
+12.4%
|
-2.5%
|
| Gross Margin |
70.7%
|
29.2%
|
| Operating Margin |
27.6%
|
18.3%
|
| Return on Equity |
68.0%
|
11.3%
|
| Dividend Yield |
0% |
0% |
| FCF Yield |
4.52%
|
11.64%
|
| Analyst Consensus |
Strong Buy
|
Strong Buy
|
Investment Thesis
AbbVie Inc. is a leading healthcare company specializing in drug manufacturing with a strong focus on immunology and aesthetics. The company is transitioning from its historical Humira dominance, which has faced loss of exclusivity, toward high-growth assets like Skyrizi and Rinvoq that are driving robust revenue growth of 12.4% in the most recent quarter. Despite strong revenue growth and a dura…
ConocoPhillips is a major player in the Energy sector focused on Oil & Gas Exploration & Production. The company demonstrates medium business quality with a stable competitive position but faces earnings pressure as reflected in a 23.4% decline in earnings and a 2.5% decline in revenue in the most recent quarter year-over-year. Despite a solid ROE of 11.3% and attractive margins (gross margin 29.…
Accumulation Zones
| Metric |
ABBV |
COP |
| Zone Low |
$198.23 |
$63.78 |
| Zone High |
$224.66 |
$72.28 |
| In Buy Zone? |
No
|
No
|